E1s and E2s first work generically across the cell to activate and prepare ubiquitin for attachment. E3 ligases then ensure that the tag is added to the right protein; as such, hundreds of specific ...
Announcing a new publication for Acta Materia Medica journal. Excessive consumption of acetaminophen (APAP) has emerged as the primary culprit behind drug-induced liver injury (DILI), with ...
Johns Hopkins University School of Medicine researchers have discovered a dual regulatory mechanism safeguarding ...
This poster introduces the background of Ubiquitins, applications of Ubiquitins in research, and featured active Ubiquitins ...
Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...
Glenmark Pharmaceuticals Ltd. has described proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 receptor-associated ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted ...
Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...
In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
Merck Sharp & Dohme LLC patents report the development of proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase (Von Hippel-Lindau disease tumor suppressor [VHL] ligands) ...
High levels of fat mass and obesity-associated protein (FTO) have been linked to increased tumor growth and resistance to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback